vestarВестник аритмологииJournal of Arrhythmology1561-86412658-7327НАО «Инкарт»vestar-721Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL ARTICLESОЦЕНКА ВЛИЯНИЯ ЛЕВОСИМЕНДАНА НА ПРОЦЕСС ОБРАТНОГО РЕМОДЕЛИРОВАНИЯ МИОКАРДА У ПАЦИЕНТОВ С ДИЛЯТАЦИОННОЙ КАРДИОМИОПАТИЕЙ ПОСЛЕ ИМПЛАНТАЦИИ КАРДИОРЕСИНХРОНИЗИРУЮЩИХ СИСТЕМASSESSMENT OF EFFECT OF LEVOSIMENDAN ON REVERSE CARDIAC REMODELING IN PATIENTS WITH DILATED CARDIOMYOPATHY AFTER IMPLANTATION OF SYSTEMS FOR CARDIAC RESYNCHRONIZATION THERAPYМарченкоР. В.MarchenkoR. V.noemail@neicon.ruДурмановС. С.DurmanovS. S.noemail@neicon.ruФГБУ «Федеральный центр сердечно-сосудистой хирургии» МЗ РФRussian Federation2015230920200793439Copyright © Марченко Р.В., Дурманов С.С., 20202020Марченко Р.В., Дурманов С.С.Marchenko R.V., Durmanov S.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestar.elpub.ru/jour/article/view/721

С целью оценки влияние левосимендана на процесс обратного ремоделирования миокарда обследованы 14 пациентов в возрасте 55,4±7,6 лет с дилятационной кардиомиопатией, осложненной хронической сердечной недостаточностью и имплантированными устройствами для сердечной ресинхронизирующей терапии.

To assess the effect of Levosimendan on reverse cardiac remodeling, 14 patients aged 55.4±7.6 years with dilated cardiomyopathy and chronic heart failure, and with implanted devices for cardiac resynchronization therapy were examined.

дилятационная кардиомиопатияхроническая сердечная недостаточностьблокада левой ножки пучка Гисасердечная ресинхронизирующая терапиялевосименданфракция выбросаdilated cardiomyopathychronic heart failureleft bundle branch blockcardiac resynchronization therapyLevosimendanejection fractionReferencesStrickberger S.A., Conti J., Daoud E.G. et al. Patient selection for cardiac resynchronization therapy: from the council on clinical cardiology subcommittee on electrocardiography and arrhythmias and the quality of care and outcomes research interdisciplinary working group, in collaboration with the Heart Rhythm Society // Circulation. 2005; 111:2146-2150Strickberger S.A., Conti J., Daoud E.G. et al. Patient selection for cardiac resynchronization therapy: from the council on clinical cardiology subcommittee on electrocardiography and arrhythmias and the quality of care and outcomes research interdisciplinary working group, in collaboration with the Heart Rhythm Society // Circulation. 2005; 111:2146-2150Yu C.M., Hayes D.L. Cardiac resynchronization therapy: state of the art 2013 // Eur Heart J. 2013; 34(19):1396- 1403.Yu C.M., Hayes D.L. Cardiac resynchronization therapy: state of the art 2013 // Eur Heart J. 2013; 34(19):1396- 1403.Cleland J., Tageldien A., Buga L. et al. Should we be trying to define responders to cardiac re synchronization therapy? // J Am Coll Cardiol Img. 2010;3(5):541-549.Cleland J., Tageldien A., Buga L. et al. Should we be trying to define responders to cardiac re synchronization therapy? // J Am Coll Cardiol Img. 2010;3(5):541-549.Richardson M., Freemantle N., Calvert M.J. et al. Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterised by dyssynchrony: a predefined analysis from the CARE-HF trial // Eur Heart J. 28 2007:1827-1834.Richardson M., Freemantle N., Calvert M.J. et al. Predictors and treatment response with cardiac resynchronization therapy in patients with heart failure characterised by dyssynchrony: a predefined analysis from the CARE-HF trial // Eur Heart J. 28 2007:1827-1834.Whinnett Z.I., Davies J.E., Willson K. Haemodynamic effects of changes in atrioventricular and interventricular delay in cardiac resynchronisation therapy show a consistent pattern: analysis of shape, magnitude and relative importance of atrioventricular and interventricular delay // Heart. 92 2006:1628-1632.Whinnett Z.I., Davies J.E., Willson K. Haemodynamic effects of changes in atrioventricular and interventricular delay in cardiac resynchronisation therapy show a consistent pattern: analysis of shape, magnitude and relative importance of atrioventricular and interventricular delay // Heart. 92 2006:1628-1632.Gervais R., Leclerc C., Shankar A. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial // Eur J Heart Fail. 11 2009:699-705.Gervais R., Leclerc C., Shankar A. Surface electrocardiogram to predict outcome in candidates for cardiac resynchronization therapy: a sub-analysis of the CARE-HF trial // Eur J Heart Fail. 11 2009:699-705.Bax J.J., Gorcsan III J. Echocardiography and Noninvasive Imaging in Cardiac Resynchronization Therapy: Results of the PROSPECT (Predictors of Response to Cardiac Resynchronization Therapy) Study in Perspective // J Am Coll Cardiol. 2009;53(21)Bax J.J., Gorcsan III J. Echocardiography and Noninvasive Imaging in Cardiac Resynchronization Therapy: Results of the PROSPECT (Predictors of Response to Cardiac Resynchronization Therapy) Study in Perspective // J Am Coll Cardiol. 2009;53(21)Yu C.M., Fung J.W., Zhang Q. et al. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure // J Card Fail. 2005 Jun;11(5 Suppl):S42-6.Yu C.M., Fung J.W., Zhang Q. et al. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure // J Card Fail. 2005 Jun;11(5 Suppl):S42-6.Brignole M., Auricchio A., Baron-Esquivias G. et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy // Eur Heart J. 2013; 34, 2281-2329.Brignole M., Auricchio A., Baron-Esquivias G. et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy // Eur Heart J. 2013; 34, 2281-2329.Bhattacharya S., Abebe K., Simon M. et al. Role of cardiac resynchronization in end-stage heart failure patients requiring inotrope therapy // J Card Fail. 2010 December ; 16(12): 931-937.Bhattacharya S., Abebe K., Simon M. et al. Role of cardiac resynchronization in end-stage heart failure patients requiring inotrope therapy // J Card Fail. 2010 December ; 16(12): 931-937.Konstantino Y., Iakobishvili Z., Arad O. et al. Urgent cardiac resynchronization therapy in patients with decompensated chronic heart failure receiving inotropic therapy. A case series. // Cardiology. 2006;106:59-62.Konstantino Y., Iakobishvili Z., Arad O. et al. Urgent cardiac resynchronization therapy in patients with decompensated chronic heart failure receiving inotropic therapy. A case series. // Cardiology. 2006;106:59-62.Cowburn P.J., Patel H., Jolliffe R.E. et al. Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure? // Eur J Heart Fail. 2005; 7:215-7.Cowburn P.J., Patel H., Jolliffe R.E. et al. Cardiac resynchronization therapy: an option for inotrope-supported patients with end-stage heart failure? // Eur J Heart Fail. 2005; 7:215-7.Hasenfuss G., Pieske B., Castell M., et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium // Circulation. 1998; 98: 2141-2147.Hasenfuss G., Pieske B., Castell M., et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium // Circulation. 1998; 98: 2141-2147.Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure // Circulation. 2000; 102: 2222-2227.Slawsky M.T., Colucci W.S., Gottlieb S.S., et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure // Circulation. 2000; 102: 2222-2227.Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with do- butamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial // Lancet. 2002; 360: 196-202.Follath F., Cleland J.G., Just H., et al. Efficacy and safety of intravenous levosimendan compared with do- butamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial // Lancet. 2002; 360: 196-202.

The authors declare that there are no conflicts of interest present.